Hosted by Unknown Host · EN · 1 episodes
Established thought leaders with verified media credentials.
Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody - JHOP
Unknown Host hosts Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody, a general show with 1 episodes published.
AONN+ is pleased to present an exclusive podcast providing peer-to-peer nursing perspectives on the current role of immunotherapy in patients with advanced multiple myeloma (MM) and introducing a new class of agents: T-c
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchShows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody, visit https://www.buzzsprout.com/2049313 for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent general coverage.
Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody is hosted by Unknown Host. The show is categorised under General and has published 1 episodes.
Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody has published 1 episodes.
Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody is accessible for guests with genuine general expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody average 19 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 11 days ago.
